Iridex Corporation announced a new partnership with EyeProGPO, an ophthalmology‑focused group purchasing organization that serves more than 1,000 practices, ambulatory surgery centers and hospitals across the United States.
Under the agreement, EyeProGPO members will receive preferred pricing on Iridex’s retina laser platform, which includes the PASCAL® system, IQ 532®, IQ 577®, and OcuLight® TX lasers. The partnership builds on an existing relationship that already covers Iridex’s Cyclo G6® glaucoma system and probes, positioning the company to capture a larger share of the U.S. ophthalmology market and increase recurring consumable revenue from its laser systems.
Iridex’s recent financial performance provides context for the partnership. In Q4 2025 the company reported total revenue of $14.7 million, up 16% year‑over‑year, with retina product revenue growing 22% to $8.9 million. Net loss narrowed to $0.2 million, and non‑GAAP adjusted EBITDA reached $0.8 million. Gross margin fell to 37% from 44% in the prior year, reflecting higher manufacturing costs and tariff impacts. For 2026, Iridex is guiding revenue of $51 million to $53 million, excluding Middle East sales, and is pursuing cost‑saving initiatives such as relocating administrative functions.
The partnership is expected to broaden access to Iridex’s proven retina technology and support value‑based purchasing decisions for EyeProGPO members. CEO Patrick Mercer described 2025 as a transformational year, noting that the company’s revenue growth, reduced operating expenses, and first‑time positive adjusted EBITDA set the stage for 2026. The deal is seen as a strategic lever to accelerate market penetration, increase consumable revenue, and reinforce Iridex’s position in the competitive retina laser market.
Analysts noted that while the partnership signals a positive step for Iridex, concerns remain about gross‑margin compression and geopolitical headwinds that could impact future revenue. The market reaction reflects a balance between optimism over expanded market reach and caution regarding the company’s margin trajectory and external risks.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.